Research programme: nanotherapeutics - Keystone Nano

Drug Profile

Research programme: nanotherapeutics - Keystone Nano

Alternative Names: Chemotherapeutic NanoJackets; Doxorubicin NanoJackets; MDs - Keystone Nano; Molecular Dots - Keystone Nano; NanoJacketed chemotherapeutics; NanoJacketed doxorubicin

Latest Information Update: 28 Oct 2016

Price : $50

At a glance

  • Originator Keystone Nano
  • Developer Keystone Nano; The Pennsylvania State University
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Breast cancer

Most Recent Events

  • 28 Oct 2016 No development reported - Preclinical for Breast cancer treatment in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top